TY - JOUR
AU1 - Rivosecchi, Ryan
AU2 - Durkin, Joseph
AU3 - Okonkwo, David
AU4 - Molyneaux, Bradley
AB - Neurocrit Care (2016) 25:359–364 DOI 10.1007/s12028-016-0271-9 ORIGINAL ARTICLE Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage 1 1 2 3 • • • Ryan M. Rivosecchi Joseph Durkin David O. Okonkwo Bradley J. Molyneaux Published online: 13 April 2016 Springer Science+Business Media New York 2016 Abstract (6.7 % in INR 1.4–1.9 group, 10 % in INR 2–3.9 group, Background The use of vitamin K antagonists is an p = 0.73). independent risk factor for the development of intracere- Conclusion The use of 4F-PCC in patients with INR bral hemorrhage (ICH). Four-factor prothrombin complex between 1.4 and 1.9 results in an effective reduction in INR concentrate (4F-PCC) is recommended for urgent reversal with similar thrombotic risks compared to patients pre- of anticoagulation in this setting. The safety and efficacy of senting with an INR of 2–3.9. 4F-PCC in ICH with subtherapeutic levels of anticoagu- lation is yet to be determined. Keywords Prothrombin complex concentrates Methods This was a retrospective, observational study of Cerebral hemorrhage  Vitamin K antagonist 4F-PCC administration data from September 2013 to July Anticoagulants 2015. Patients with spontaneous or traumatic ICH with initial INR 1.4–1.9 were compared to 
TI - Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage
JF - Neurocritical Care
DO - 10.1007/s12028-016-0271-9
DA - 2016-04-13
UR - https://www.deepdyve.com/lp/springer-journals/safety-and-efficacy-of-warfarin-reversal-with-four-factor-prothrombin-ZUwXJsB1G0
SP - 359
EP - 364
VL - 25
IS - 3
DP - DeepDyve
ER -